Filing Flows › Verrica Pharmaceuticals (VRCA) › Q4 2024
Verrica Pharmaceuticals (VRCA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 11, 2025
Verrica Pharmaceuticals (VRCA) reported revenue of $344K for the fourth quarter 2024 (Q4 2024), -83% from a year earlier.
Verrica Pharmaceuticals, Q4 2024: revenue $344K (-83% year over year), net loss $16.2M, operating cash flow −$16.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $344K | — | -83% |
| Operating profit | −$11.4M | — | — |
| Net earnings | −$16.2M | — | — |
| Operating cash flow | −$16.1M | — | — |
What changed
Revenue was $344K in Q4 2024, down 83% year over year. Product was the largest line at 92% of revenue.
Operating costs exceeded revenue by $11.4M, an operating margin of -3316.9%. Total costs fell 53% while revenue fell 83%. The quarter ended with a net loss of $16.2M.
Operating cash flow was −$16.1M. Non-cash charges added back $54K of depreciation and $756K of share-based compensation.
Questions
What was Verrica Pharmaceuticals' revenue in the fourth quarter 2024?
Verrica Pharmaceuticals (VRCA) reported revenue of $344K for the fourth quarter 2024 (Q4 2024), -83% from a year earlier.